The use of sirolimus should be restricted in liver transplantation

Omar Massoud, Russell H. Wiesner

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Sirolimus and mTOR inhibitors are important additions to the therapeutic armamentarium to prevent allograft rejection, but their role in liver transplantation is evolving. De novo use of Sirolimus in the early post-transplant period has undoubtedly been influenced by the high incidence of hepatic artery thrombosis and decreased patient and graft survival leading to a black box warning. The jury remains undecided on the role of conversion from CNIs to mTOR inhibitors in those developing renal insufficiency and it must be noted that a second warning was issued by the FDA because of decreased survival in those conversion studies. Finally, the anti-atherogenic, antiviral, and anti-neoplastic effects associated with Sirolimus, which might favor their use in certain liver transplant patients, need further evaluation before firm recommendations can be made.

Original languageEnglish (US)
Pages (from-to)288-290
Number of pages3
JournalJournal of Hepatology
Volume56
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Sirolimus
Liver Transplantation
Drug Labeling
Transplants
Hepatic Artery
Graft Survival
Renal Insufficiency
Antiviral Agents
Allografts
Thrombosis
Survival
Liver
Incidence
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

The use of sirolimus should be restricted in liver transplantation. / Massoud, Omar; Wiesner, Russell H.

In: Journal of Hepatology, Vol. 56, No. 1, 01.2012, p. 288-290.

Research output: Contribution to journalArticle

Massoud, Omar ; Wiesner, Russell H. / The use of sirolimus should be restricted in liver transplantation. In: Journal of Hepatology. 2012 ; Vol. 56, No. 1. pp. 288-290.
@article{386fed8f60dd42a1aa34a35ec183e5cb,
title = "The use of sirolimus should be restricted in liver transplantation",
abstract = "Sirolimus and mTOR inhibitors are important additions to the therapeutic armamentarium to prevent allograft rejection, but their role in liver transplantation is evolving. De novo use of Sirolimus in the early post-transplant period has undoubtedly been influenced by the high incidence of hepatic artery thrombosis and decreased patient and graft survival leading to a black box warning. The jury remains undecided on the role of conversion from CNIs to mTOR inhibitors in those developing renal insufficiency and it must be noted that a second warning was issued by the FDA because of decreased survival in those conversion studies. Finally, the anti-atherogenic, antiviral, and anti-neoplastic effects associated with Sirolimus, which might favor their use in certain liver transplant patients, need further evaluation before firm recommendations can be made.",
author = "Omar Massoud and Wiesner, {Russell H.}",
year = "2012",
month = "1",
doi = "10.1016/j.jhep.2011.06.012",
language = "English (US)",
volume = "56",
pages = "288--290",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The use of sirolimus should be restricted in liver transplantation

AU - Massoud, Omar

AU - Wiesner, Russell H.

PY - 2012/1

Y1 - 2012/1

N2 - Sirolimus and mTOR inhibitors are important additions to the therapeutic armamentarium to prevent allograft rejection, but their role in liver transplantation is evolving. De novo use of Sirolimus in the early post-transplant period has undoubtedly been influenced by the high incidence of hepatic artery thrombosis and decreased patient and graft survival leading to a black box warning. The jury remains undecided on the role of conversion from CNIs to mTOR inhibitors in those developing renal insufficiency and it must be noted that a second warning was issued by the FDA because of decreased survival in those conversion studies. Finally, the anti-atherogenic, antiviral, and anti-neoplastic effects associated with Sirolimus, which might favor their use in certain liver transplant patients, need further evaluation before firm recommendations can be made.

AB - Sirolimus and mTOR inhibitors are important additions to the therapeutic armamentarium to prevent allograft rejection, but their role in liver transplantation is evolving. De novo use of Sirolimus in the early post-transplant period has undoubtedly been influenced by the high incidence of hepatic artery thrombosis and decreased patient and graft survival leading to a black box warning. The jury remains undecided on the role of conversion from CNIs to mTOR inhibitors in those developing renal insufficiency and it must be noted that a second warning was issued by the FDA because of decreased survival in those conversion studies. Finally, the anti-atherogenic, antiviral, and anti-neoplastic effects associated with Sirolimus, which might favor their use in certain liver transplant patients, need further evaluation before firm recommendations can be made.

UR - http://www.scopus.com/inward/record.url?scp=83555161510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555161510&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.06.012

DO - 10.1016/j.jhep.2011.06.012

M3 - Article

C2 - 21741926

AN - SCOPUS:83555161510

VL - 56

SP - 288

EP - 290

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -